Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the ACE Inhibitors Market Evolve in Terms of Growth and Size by 2029?

The market of ACE inhibitors has seen stable growth in the past years. Its value is projected to increase from $7.15 billion in 2024 to $7.41 billion in 2025, indicating a compound annual growth rate (CAGR) of 3.6%. The significant growth during the historic period can be traced back to factors such as a surge in the occurrence of cardiovascular diseases, an increase in the elderly population, proven clinical effectiveness and safety, the spread of diabetes, as well as regulatory approval and guidelines.

In the coming years, the market size for ACE inhibitors is set to witness significant growth, reaching $9.42 billion by 2029, expanding at a compound annual growth rate (CAGR) of 6.2%. The upturn during the forecast period can be associated with the mounting global incidence of cardiovascular ailments, the enlargement of hypertension treatment guidelines, the progression of combination therapies, emphasis on heart failure management, and an increase in awareness and access to healthcare. Noteworthy trends expected during this period involve a concentration on kidney protection, a predilection for renin-angiotensin system inhibitors, generic competition and pricing challenges, patient-focused medical care practices, as well as regulatory modifications and safety assessments.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10671&type=smp

What factors are expected to fuel ACE Inhibitors market growth in the coming years?

The growth of the ACE inhibitors market is being propelled by the rising incidence of hypertension disorders. Hypertension, often referred to in medical terms as high blood pressure, results from an increased pressure in the blood vessels. Angiotensin-converting enzyme inhibitors, commonly known as ACE inhibitors, are a group of drugs used to manage and treat this condition, functioning to relax the blood vessels and thereby reduce blood pressure and enhance blood circulation. As reported by the World Health Organization in March 2023, a Switzerland-based arm of the United Nations that specializes in global health matters, about 1.28 billion adults aged 30 to 79 worldwide suffered from hypertension, with two-thirds of this population living in low and middle-income countries. Over the past 30 years, an additional 650 million adults aged 30 to 79 have developed hypertension. Surprisingly, an estimated 46% of adults with hypertension have no knowledge of their condition due to lack of diagnosis. The number of adults aged 30-79 with hypertension has spiked by 650 million in the last 30 years. Approximately 46% of individuals suffering from hypertension remain oblivious to their condition because they haven’t been diagnosed. Consequently, the ACE inhibitors market is experiencing growth due to the escalating prevalence of hypertension disorders.

What Are The Key Findings From The Segmentation Analysis Of The ACE Inhibitors Market?

The ace inhibitors market covered in this report is segmented –

1) By Type: Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents

2) By Drug: Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Other Drugs

3) By Dosage Form: Oral Tablets, Oral Solutions

4) By Application: Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Other Applications

5) By End-Users: Hospitals, Online Drug Stores, Other End-Users

Subsegments:

1) By Sulfhydryl-Containing Agents: Captopril, Zofenopril

2) By Dicarboxylate-Containing Agents: Enalapril, Lisinopril, Ramipril, Quinapril, Benazepril, Perindopril

3) By Phosphonate-Containing Agents: Fosinopril

Which Trends Are Expected To Shape The Future Of The ACE Inhibitors Market?

A primary trend gaining momentum in the ACE inhibitors market is the focus on product innovations. The leading corporations in this market channel their energies towards creating pioneering products to solidify their standing and get an edge in the competition. A case in point is Travere Therapeutics, a biopharmaceutical establishment from the United States, which received FDA approval for FILSPARI (sparsentan), a unique non-immunosuppressive therapy for patients with IgA nephropathy (IgAN) in February 2023. The therapy includes systemic glucocorticoids, angiotensin-converting enzyme (ACE) inhibitors, and antihypertensive drugs like angiotensin-receptor blockers (ARBs). It is the solitary non-immunosuppressive therapy that has been approved. An oral medication to be taken once daily, it is intended to treat adults with primary IgAN who are prone to fast disease progression and usually show a UPCR of less than 1.5 g/g and proteinuria.

What Are The Most Active Companies In The ACE Inhibitors Market Today?

Major companies operating in the ACE inhibitors market include Pfizer Inc., Novartis AG, Johnson & Johnson Private Limited, Merck KGaA, Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Co., Takeda Pharmaceuticals Company, Daiichi Sankyo Company Ltd., UCB Schwarz Pharma Inc., Endo International plc, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, Bausch Health Companies Inc., Dr. Reddy’s Laboratories, Abbott Laboratories, Eli Lilly and Company, Cipla Limited, GlaxoSmithKline plc, Cadila Healthcare Limited, AbbVie Inc., Sandoz Group AG, Accord Healthcare Ltd., AstraZeneca plc, Lupin Limited, Macleods Pharmaceuticals Limited, Zydus lifescience Ltd., Apotex Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

Which Regional Markets Are Attracting The Most Investment In ACE Inhibitors?

North America was the largest region in the ACE inhibitors market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in the ace inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10671&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model